New study to reveal how standard brain tumor treatments impact immune response
NCT ID NCT07568782
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how the immune system changes in people with glioblastoma, an aggressive brain cancer, after they have surgery and chemotherapy. Researchers will take blood samples over six months to measure immune cells and signals. The goal is to understand the body's immune response to standard treatments, which may help improve future therapies. About 17 adults with suspected glioblastoma will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Lille
Lille, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- A simple lotion duo may shield skin from Tumor-Treating fields
- Can a One-Two punch slow recurrent brain cancer?